These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 11859653)

  • 1. [Biphosphonates in the treatment of bone metastasis of prostatic cancer].
    Paule B; Cicco A
    Prog Urol; 2001 Dec; 11(6):1205-12. PubMed ID: 11859653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A
    J Urol; 2001 Dec; 166(6):2023-31. PubMed ID: 11696699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
    Saad F
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of bone turnover in prostate cancer.
    Garnero P
    Cancer Treat Rev; 2001 Jun; 27(3):187-92; discussion 193-6. PubMed ID: 11417970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
    Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of bisphosphonates in the management of bone metastases in prostate cancer.
    Saad F; Chi K; Fleshner N
    Can J Urol; 2004 Oct; 11(5):2376-82. PubMed ID: 15576002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of bone health in prostate cancer.
    Lattouf JB; Saad F
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
    Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
    [No Abstract]   [Full Text] [Related]  

  • 11. Natural history and treatment of bone complications in prostate cancer.
    Saad F; Clarke N; Colombel M
    Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
    Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
    Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of bisphosphonates in prostate cancer.
    Oades GM; Coxon J; Colston KW
    Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    Saad F; Lipton A
    BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates in prostate carcinoma.
    Adami S
    Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of prophylactic effect of incadronate on skeletal lesions associated with implants of prostate cancer.
    Hikosaka A; Futakuchi M; Ogiso T; Suzuki S; Kohri K; Shirai T
    Eur Urol; 2006 Jan; 49(1):176-82. PubMed ID: 16310925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
    Vogel CL; Yanagihara RH; Wood AJ; Schnell FM; Henderson C; Kaplan BH; Purdy MH; Orlowski R; Decker JL; Lacerna L; Hohneker JA
    Oncologist; 2004; 9(6):687-95. PubMed ID: 15561812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
    Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
    Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates for treatment and prevention of bone metastases.
    Michaelson MD; Smith MR
    J Clin Oncol; 2005 Nov; 23(32):8219-24. PubMed ID: 16278476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
    Saad F; Sternberg CN
    Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.